Search documented disagreements and product cautions across the local library. Compare complete source versions on the drug page before choosing a regimen.
Search medication names and documented issues only. Do not enter patient information. This directory submits search filters to the server; the within-drug text finder remains a separate local feature.
A difference is not always a contradiction
Compare indication, formulation, route, population, renal method, dialysis conditions and source date. A safety update or source-quality failure is not an alternative dose. These notes are not independent clinical approval, and sources are not ranked or averaged.
IV cetirizine is not the oral levocetirizine renal schedule
The selected QUZYTTIR IV label does not require a renal dose change in the stated populations, but use below age 6 with renal or hepatic impairment is not recommended. Oral levocetirizine has a separate renal schedule and exclusions.
What to reconcile
Match the ingredient, route, age and acute-urticaria indication. Do not transfer an oral schedule to this IV product or turn a pediatric not-recommended statement into an adult contraindication.
1 source identities and dates
QUZYTTIR - IV cetirizine, renal and age-specific instructions
DailyMed | Source revision: March 2026 QUZYTTIR IV cetirizine for acute urticaria. Renal guidance applies with the explicit under-6-year exclusion.
Unstudied renal PK must not appear as no adjustment needed
The official and mirror sections agree on an evidence gap, not on an established CKD regimen.
What to reconcile
Keep renal and dialysis uncertainty visible, with stone and hydration precautions.
2 source identities and dates
GlobalRPh RX List - EVOXAC
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. EVOXAC oral cevimeline capsules for dry-mouth symptoms in Sjogren syndrome; kidney-stone precautions and renal PK gaps are distinct.
The older mirror calls for conservative dosing in renal impairment and highlights prolonged hypoglycemia risk.
What to reconcile
Do not relabel the geriatric example as a renal schedule. Current-product verification and treatment appropriateness remain open.
1 source identities and dates
GlobalRPh RX List - DIABINESE
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. Dated DIABINESE chlorpropamide mirror; included as a renal-risk reference, not a treatment preference or proof of current product availability.
Nonabsorption does not eliminate acid-base precautions
The PREVALITE mirror identifies hyperchloremic acidosis concerns with renal insufficiency, volume depletion and spironolactone.
What to reconcile
Keep the qualitative warning visible; do not invent a clearance threshold or monitoring frequency.
1 source identities and dates
GlobalRPh RX List - PREVALITE
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. PREVALITE cholestyramine powder for oral suspension; brand-specific excipient and administration details must not be generalized to all products.
Preserved recovery does not imply identical onset or metabolite exposure
The source describes slower ESRD onset and longer metabolite half-lives despite similar recovery.
What to reconcile
Preserve neuromuscular monitoring and anesthetic context. Do not convert a PK study dose into a universal intubating dose.
1 source identities and dates
GlobalRPh RX List - NIMBEX
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. NIMBEX IV neuromuscular blocker in a monitored anesthetic/critical-care setting; not a sedative or analgesic substitute.
MAVENCLAD: oral multiple-sclerosis restriction is not injectable oncology dosing
The oral MS product has its own renal eligibility limit. Injectable cladribine evidence does not repair or override that limit.
What to reconcile
Confirm indication and formulation before using a cladribine renal source.
1 source identities and dates
GlobalRPh RX List - MAVENCLAD
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. MAVENCLAD oral cladribine for multiple sclerosis; not injectable cladribine.
The mirror reports no adjustment in the studied range, but severe-renal experience and dialyzability remain uncertain.
What to reconcile
Display the evidence gap explicitly and confirm exact current labeling; do not invent a supplement.
1 source identities and dates
GlobalRPh RX List - ONFI
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. ONFI oral clobazam; severe renal impairment and dialysis are not covered by the mild/moderate finding.
Renal thresholds agree in the selected passages, but source revisions differ (manufacturer 2019; RX 2022). Full current-label reconciliation is pending.
What to reconcile
Confirm the current oncology protocol, exact patient population and label before use. No recommendation is inferred for CrCl <30 or dialysis.
2 source identities and dates
Clofarabine IV injection (Clolar) - selected label sections
Sanofi / CLOLAR prescribing information | Source revision: 12/2019 CLOLAR IV injection: labeled pediatric population ages 1 to 21 with relapsed/refractory ALL after at least two prior regimens. Not a general adult oncology dosing protocol.
Clofarabine IV injection (Clolar) - RX mirror renal summary
GlobalRPh RX List / product-label mirror | Source revision: 07/2022 CLOLAR IV injection: labeled pediatric population ages 1 to 21 with relapsed/refractory ALL after at least two prior regimens. Not a general adult oncology dosing protocol.
ONYDA XR: no post-HD supplement does not establish the starting dose
Minimal removal during routine HD does not cancel the need for impairment-based initiation and cautious titration.
What to reconcile
Monitor hypotension and bradycardia; do not invent a pediatric renal table.
1 source identities and dates
GlobalRPh RX List - ONYDA XR
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. Clonidine - ONYDA XR oral suspension; selected source sections only, not a complete prescribing monograph.
No dialysis supplement does not mean an unadjusted starting dose
The selected official and mirror paragraphs require impairment-based initiation and cautious titration, but give no numerical renal ladder.
What to reconcile
Keep the no-supplement statement separate from starting-dose assessment and other clonidine products.
2 source identities and dates
GlobalRPh RX List - ONYDA XR
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. ONYDA XR extended-release oral suspension for ADHD in pediatric patients 6 years and older; not an mg-for-mg substitute for other clonidine products.
DailyMed / NextWave Pharmaceuticals, Inc | Source revision: 4/2025 ONYDA XR extended-release oral suspension for ADHD in pediatric patients 6 years and older; not an mg-for-mg substitute for other clonidine products.
A creatinine-secretion effect must not mask genuine renal injury
The mirror separates inhibition of creatinine secretion from TDF-associated renal injury and combination-specific restrictions.
What to reconcile
Assess the full regimen and renal-safety findings; do not dismiss every creatinine rise or transfer TDF rules to TAF.
1 source identities and dates
GlobalRPh RX List - TYBOST
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. TYBOST cobicistat as a pharmacokinetic enhancer; renal restrictions depend on the complete antiretroviral regimen, including TDF versus TAF.
Gout prophylaxis, flare treatment and interactions differ
The COLCRYS gout source has different dialysis instructions for prophylaxis and flares. Renal/hepatic impairment plus strong CYP3A4 or P-gp inhibition is a contraindication, not merely another dose-reduction row.
What to reconcile
Check interacting medicines and existing prophylaxis; do not substitute LODOCO cardiovascular instructions.
1 source identities and dates
GlobalRPh RX List - COLCRYS
GlobalRPh-hosted RX List | Source revision: Revision not established in selected retrieval COLCRYS oral tablets: selected gout prophylaxis/flare renal instructions only.
Cardiovascular colchicine is not a gout or dialysis regimen
The dated LODOCO mirror has product-specific renal and interaction contraindications.
What to reconcile
Confirm the exact current cardiovascular product before use; do not import gout schedules, reduce contraindicated combinations by assumption, or supply a dialysis dose.
1 source identities and dates
GlobalRPh RX List - LODOCO
GlobalRPh-hosted RX List | Source revision: 6/2023 LODOCO 0.5 mg oral cardiovascular-risk-reduction product; do not import gout or familial Mediterranean fever regimens.
GLOPERBA: prophylaxis is not acute-flare treatment
These renal instructions are for prophylaxis with the specified oral solution, not acute treatment. Organ impairment plus interacting drugs creates restrictions beyond the dose table.
What to reconcile
Verify indication, solution concentration, renal/hepatic status and interactions. A dialysis prophylaxis schedule must not be reused for an acute attack.
1 source identities and dates
GlobalRPh RX List - Gloperba
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. GLOPERBA 0.12 mg/mL for gout-flare prophylaxis, not treatment of an acute attack.
Stable-CKD pharmacokinetics do not justify treatment through nephritis
Baseline renal PK findings and immune-mediated nephritis hold/stop criteria answer different questions.
What to reconcile
When kidney injury develops during treatment, assess cause and toxicity grade rather than selecting a baseline renal band and automatically continuing therapy.
1 source identities and dates
GlobalRPh RX List - Unloxcyt
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. Adult UNLOXCYT oncology infusion; renal toxicity management is distinct from baseline CKD.
Immediate-release cystine sampling differs from delayed release
The mirror describes 5-6-hour post-dose monitoring. Its overdose dialysis discussion is not a maintenance regimen.
What to reconcile
Keep CYSTAGON separate from the official PROCYSBI 12-hour trough instruction.
1 source identities and dates
GlobalRPh RX List - CYSTAGON
GlobalRPh-hosted RX List | Source revision: Source revision date not established in selected retrieval. CYSTAGON immediate-release oral cysteamine for nephropathic cystinosis; keep separate from PROCYSBI delayed-release product.
Only documented issues are searchable here. Absence of a note is not agreement. A label mirror and the original label are not independent corroboration, and a source's retrieval date is not its revision date.